Conclusion
Our retrospective analysis suggested that MC demonstrated clinical
benefits for relapsed or refractory pediatric cancers; about half of the
progressive tumors presented tumor stabilization and prolonged survival
time with higher QOL. The treatment was well tolerated in previously
heavily treated patients, and the incidence of AEs decreased compared to
conventional chemotherapy. Although large-scale analysis is lacking and
many issues need to be resolved, MC can be an important part of cancer
treatment.